Laura Fernanda Neira

Mrs. Laura Fernanda Neira

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Materials
Verified
Journal Article
Open access
PDF file
LCLaura María Chaparro
Laura María Chaparro
LNLaura Fernanda Neira
Laura Fernanda Neira
DVDANIEL RICARDO MOLINA VELASCO
DANIEL RICARDO MOLINA VELASCO
DRDiego Rivera-Barrera
Diego Rivera-Barrera
MCMaribel Castañeda
Maribel Castañeda
PEPatricia Escobar
Patricia Escobar
The production of waxes from vegetable oils, such as palm oil, for use as a base material in products for human applications is an alternative to those derived from petroleum and animals. Seven palm oil–derived waxes, called biowaxes (BW1–BW7) in this work, were obtained by catalytic hydrotreating of refined and bleached African palm oil and refined palm kernel oil. They were characterized by three properties: compositional, physicochemical (melting point, penetration value, and pH), and biological (sterility, cytotoxicity, phototoxicity, antioxidant, and irritant). Their morphologies and chemical structures were studied by SEM, FTIR, UV–Vis, and 1H NMR. The BWs presented structures and compositions similar to natural biowaxes (beeswax and carnauba). They had a high concentration of waxy esters (17%–36%) with long alkyl chains (C, 19–26) per carbonyl group, which are related to high melting points (<20–47.9 °C) and low penetration values (2.1–3.8 mm). They also proved to be sterile materials with no cytotoxic, phototoxic, antioxidant, or irritant activity. The biowaxes studied could be used in cosmetic and pharmacological products for human use.

9 November 2023 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
LNLaura Fernanda Neira
Laura Fernanda Neira
JMJulio Cesar Mantilla
Julio Cesar Mantilla
PEPatricia Escobar
Patricia Escobar
A study was conducted on BALB/c mice infected with Leishmania (Leishmania) amazonensis to analyse the effects of 0.5% miltefosine (MTF) hydrogel treatment on cutaneous leishmaniasis (CL) lesions. The mice were treated for 25 days topically, and lesion sizes, parasite loads, histopathology, ultrastructure, cytokines including interleukin 4 (IL-4), tumour necrosis factor alfa (TNFα), interferon gamma (IFNγ), IL-10, and vascular endothelial growth factor (VEGF) profiles were evaluated on days 0, 12, 25, and 85. After 12 days of treatment, the lesion sizes and parasite numbers decreased. By day 60 post treatment, there were no lesions and only a few parasites. At day 25, there was a temporary papillomatosis reaction, an increase in mast cells, a few giant cells, and granulomas, and a decrease in diffuse inflammatory infiltrate and parasites. Transmission electron microscopy (TEM) examination showed early ultrastructural changes, including macrophages without parasites and vacuoles containing electrodense material. At the different evaluated times, the cytokine regulation indexes (ICRs) decreased for IL-4, TNFα, and VEGF. According to the study, the 0.5% MTF hydrogel was effective and showed positive results from the early stages of usage. The MTF directly targeted parasites, downregulated the release of IL-4, TNFα, and VEGF, increased mast cell production, and induced granuloma reaction during evaluation periods.

27 September 2025 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
LNLaura Fernanda Neira
Laura Fernanda Neira
HCHéllida Marina Costa-Silva
Héllida Marina Costa-Silva
JRJuliana Martins Ribeiro
Juliana Martins Ribeiro
SMSilvane Maria Fonseca Murta
Silvane Maria Fonseca Murta
PEPatricia Escobar
Patricia Escobar
Miltefosine (MTF) is currently the only available oral treatment for leishmaniasis. However, increasing reports of therapeutic failure have raised concerns about emerging resistance. This study aimed to investigate the effects of reduced MTF susceptibility loss in the protozoan parasite Leishmania (Leishmania) amazonensis, with a particular focus on its impact on key biological and molecular parameters. Two distinct Leishmania lines (LaR-40 Line 1 and Line 2) were generated through stepwise in vitro selection with increasing concentrations of MTF, reaching up to 40 μM MTF. They were compared to their wild-type counterpart (LaWT). After 12 weeks of selection, LaR-40 promastigotes exhibited IC50 values that were 4- to 8-fold higher than those of LaWT, with resistance remaining stable even after three months without drug pressure and following passage through BALB/c mice. No cross-resistance was detected against pentamidine, ketoconazole, or amphotericin B. MTF-resistant parasites exhibited reduced reactive oxygen species production, reduced lipid droplets (LD) abundance (in LaR-40 Line 1), delayed lesion onset, and smaller cutaneous lesions in mice, while maintaining normal infectivity in THP-1 macrophages. Quantitative RT-PCR analysis revealed consistent downregulation of the miltefosine transporter (mt) gene in both MTF-resistant lines, indicating that reduced drug uptake is the main mechanism underlying resistance. Line-specific changes, such as the upregulation of the serine palmitoyltransferase (spt) gene or the downregulation of the trypanothione reductase (tryr) gene, suggest that distinct metabolic pathways may act in a compensatory manner to reinforce resistance once transporter function is impaired. These findings indicate that MTF resistance in L. amazonensis is polygenic, stable, and adaptable. Routine monitoring of mt gene expression, combined with therapeutic strategies that target lipid or redox metabolism alongside drug uptake pathways, may help preserve the efficacy of current treatment regimens against leishmaniasis.

31 August 2026 in Gels
Verified
Journal Article
Open access
PDF file
DBDiana Paola Peña Burgos
Diana Paola Peña Burgos
LNLaura Fernanda Neira
Laura Fernanda Neira
PEPatricia Escobar
Patricia Escobar
We previously demonstrated the therapeutic potential of a 0.5% miltefosine carbopol-based gel (G-MTF) in experimental cutaneous leishmaniasis (CL). To support formulation optimisation before clinical evaluation, this study assessed whether G-MTF retained antileishmanial activity after storage at different temperatures and durations and evaluated its dose–response following topical application to CL lesions in BALB/c mice infected with Leishmania amazonensis. Storage effects on some physicochemical and morphological properties, sterility, and MTF detection were also assessed. In vitro antileishmanial activity was largely maintained, although prolonged storage at 35–45 °C moderately reduced potency. During 60 days of follow-up, CL lesions reactivated in 17% of the 118 treated mice, with most reactivations occurring after treatment with G-MTF formulations stored for 3–6 months at 35–45 °C. Dose–response analysis showed concentration-dependent effects on lesion reduction and parasite burden, with estimated ED50 values of 3.64 and 4.02 mg/kg, respectively. All carbopol-based gel formulations remained sterile and retained physicochemical characteristics at 8–28 °C, with pH values within the normal skin range. Storage at 8 °C increased viscosity and reduced spreadability, whereas higher temperatures increased swelling. MALDI-TOF MS demonstrated that MTF remained detectable after prolonged storage, while SEM showed preserved morphology at 8–28 °C. Overall, carbopol-based G-MTF maintained therapeutic activity and acceptable physicochemical characteristics for up to six months at 8–28 °C. Validated quantitative stability-indicating and drug-release methods are needed to confirm MTF chemical stability and drug availability in the carbopol-based gel.